Trial Outcomes & Findings for NB-001 in Children and Adolescents With 22q11 Deletion Syndrome (NCT NCT05290493)

NCT ID: NCT05290493

Last Updated: 2025-02-10

Results Overview

Type, frequency, severity, and causality of treatment-emergent adverse events (TEAEs),treatment-emergent serious adverse events (TESAEs), clinically significant changes from baseline in laboratory tests, electrocardiograms (ECGs), vital signs, and physical examination findings during treatment with NB-001.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

37 participants

Primary outcome timeframe

6 weeks (Day 42/ET)

Results posted on

2025-02-10

Participant Flow

Participant milestones

Participant milestones
Measure
Placebo (6 Weeks) Then Washout (1 Week) Then NB-001 (6 Weeks)
Subjects received Placebo for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week. Subjects then received NB-001 for the subsequent 6-week period (Treatment Period 2).
NB-001 (6 Weeks) Then Washout (1 Week) Then Placebo (6 Weeks)
Subjects received NB-001 for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week. Subjects then received Placebo for the subsequent 6-week period (Treatment Period 2).
Overall Study
STARTED
18
19
Overall Study
COMPLETED
15
17
Overall Study
NOT COMPLETED
3
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Placebo (6 Weeks) Then Washout (1 Week) Then NB-001 (6 Weeks)
Subjects received Placebo for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week. Subjects then received NB-001 for the subsequent 6-week period (Treatment Period 2).
NB-001 (6 Weeks) Then Washout (1 Week) Then Placebo (6 Weeks)
Subjects received NB-001 for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week. Subjects then received Placebo for the subsequent 6-week period (Treatment Period 2).
Overall Study
Withdrawal by Subject
2
2
Overall Study
Adverse Event
1
0

Baseline Characteristics

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Placebo (6 Weeks) Then Washout (1 Week) Then NB-001 (6 Weeks)
n=17 Participants
Subjects received Placebo for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week. Subjects then received NB-001 for the subsequent 6-week period (Treatment Period 2).
NB-001 (6 Weeks) Then Washout (1 Week) Then Placebo (6 Weeks)
n=17 Participants
Subjects received NB-001 for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week. Subjects then received Placebo for the subsequent 6-week period (Treatment Period 2).
Total
n=34 Participants
Total of all reporting groups
Age, Continuous
12.1 Years
STANDARD_DEVIATION 3.12 • n=99 Participants
11.9 Years
STANDARD_DEVIATION 3.30 • n=107 Participants
12.0 Years
STANDARD_DEVIATION 3.16 • n=206 Participants
Sex: Female, Male
Female
6 Participants
n=99 Participants
6 Participants
n=107 Participants
12 Participants
n=206 Participants
Sex: Female, Male
Male
11 Participants
n=99 Participants
11 Participants
n=107 Participants
22 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=99 Participants
1 Participants
n=107 Participants
3 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
15 Participants
n=99 Participants
15 Participants
n=107 Participants
30 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
2 Participants
n=99 Participants
0 Participants
n=107 Participants
2 Participants
n=206 Participants
Race (NIH/OMB)
White
13 Participants
n=99 Participants
15 Participants
n=107 Participants
28 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Region of Enrollment
Canada
3 participants
n=99 Participants
3 participants
n=107 Participants
6 participants
n=206 Participants
Region of Enrollment
United States
14 participants
n=99 Participants
14 participants
n=107 Participants
28 participants
n=206 Participants
Reproductive Potential
Yes
8 Participants
n=99 Participants
9 Participants
n=107 Participants
17 Participants
n=206 Participants
Reproductive Potential
No
9 Participants
n=99 Participants
8 Participants
n=107 Participants
17 Participants
n=206 Participants

PRIMARY outcome

Timeframe: 6 weeks (Day 42/ET)

Population: Safety Analysis Set: Includes all subjects who receive at least one capsule (100 mg) of IP.

Type, frequency, severity, and causality of treatment-emergent adverse events (TEAEs),treatment-emergent serious adverse events (TESAEs), clinically significant changes from baseline in laboratory tests, electrocardiograms (ECGs), vital signs, and physical examination findings during treatment with NB-001.

Outcome measures

Outcome measures
Measure
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
Placebo
n=34 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
Safety and Tolerability of NB-001
CTCAE Grade 4: Life-threatening
0 Participants
0 Participants
Safety and Tolerability of NB-001
TEAE Leading to Premature Withdrawal from the Study
0 Participants
1 Participants
Safety and Tolerability of NB-001
Subjects Reporting at Least One TEAE
18 Participants
24 Participants
Safety and Tolerability of NB-001
CTCAE Grade 1: Mild
14 Participants
20 Participants
Safety and Tolerability of NB-001
CTCAE Grade 2: Moderate
4 Participants
4 Participants
Safety and Tolerability of NB-001
CTCAE Grade 3: Severe
0 Participants
0 Participants
Safety and Tolerability of NB-001
CTCAE Grade 5: Causing Death
0 Participants
0 Participants
Safety and Tolerability of NB-001
TEAE Relationship: Not Related
12 Participants
20 Participants
Safety and Tolerability of NB-001
TEAE Relationship: Related
6 Participants
4 Participants
Safety and Tolerability of NB-001
TEAE Leading to Discontinuation of IP
0 Participants
1 Participants
Safety and Tolerability of NB-001
TEAE Requiring Temporary Dose Interruption of IP
1 Participants
0 Participants
Safety and Tolerability of NB-001
TEAE Requiring Dose Reduction of IP
0 Participants
1 Participants
Safety and Tolerability of NB-001
TEAE of Special Interest
2 Participants
0 Participants
Safety and Tolerability of NB-001
TEAE Causing Death
0 Participants
0 Participants
Safety and Tolerability of NB-001
Subjects Reporting at Least One TESAE
0 Participants
0 Participants

SECONDARY outcome

Timeframe: 6 weeks (Day 42/ET)

Population: Full Analysis Set (FAS): Includes all subjects in the Enrolled Analysis Set (those who meet all eligibility criteria and consent to participate in study) who have at least one valid post-baseline efficacy evaluation within each treatment period. Subjects are analyzed based on the treatment to which they were randomized in each treatment period.

The CGI-I scale is a 7-point scale that measures how much a patient's condition has improved or worsened over time. The CGI-I is scored on a scale of 1-7, with a score of 1 indicating "Very much improved" and 7 indicating "Very much worse". The least squares mean of the score on the CGI-I scale at the end of the 6-week treatment period is reported here.

Outcome measures

Outcome measures
Measure
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
Placebo
n=33 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
Treatment Effect of NB-001 on the Clinical Global Impression Improvement (CGI-I) Scale
3.34 Score on a scale
Standard Error 0.154
3.69 Score on a scale
Standard Error 0.154

SECONDARY outcome

Timeframe: 6 weeks (Day 42/ET)

Population: Full Analysis Set: Includes all subjects in the Enrolled Analysis Set (those who meet all eligibility criteria and consent to participate in study) who have at least one valid post-baseline efficacy evaluation within each treatment period. Subjects are analyzed based on the treatment to which they were randomized in each treatment period.

CGI-S: 7-point scale that measures a participant's overall disease severity. A 1-point improvement in the CGI-S scale is an appropriate meaningful change threshold. Possible scores are: 1 = Normal, not at all impaired; 2 = Borderline impaired; 3 = Mildly impaired; 4 = Moderately impaired; 5 = Markedly impaired; 6 = Severely impaired; 7 = Among the most extremely impaired patients.

Outcome measures

Outcome measures
Measure
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
Placebo
n=33 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
Treatment Effect of NB-001 on the Clinical Global Impression Severity (CGI-S) Scale
4.14 score on a scale
Standard Error 0.121
4.12 score on a scale
Standard Error 0.121

SECONDARY outcome

Timeframe: 6 weeks (Day 42/ET)

Population: Full Analysis Set: Includes all subjects in the Enrolled Analysis Set (those who meet all eligibility criteria and consent to participate in study) who have at least one valid post-baseline efficacy evaluation within each treatment period. Subjects are analyzed based on the treatment to which they were randomized in each treatment period.

The PARS is a clinician-rated instrument for assessing severity of anxiety symptoms associated with common anxiety disorders. The first section is a 50-item symptom checklist and the second section is comprised of 7 severity/impairment items reflecting the severity/impairment of all symptoms noted in the first section. The PARS total severity score is calculated as the sum of items 2, 3, 5, 6, and 7 from the second section of the instrument. Each item is rated on a 6-point Likert scale from 0-5 with the higher scores indicating more severe anxiety. The total severity score can range from a minimum value of 0 to a maximum value of 25. Higher scores indicate more severe anxiety. Additionally, per protocol, at baseline, a score of \>12 on the PARS 5-item total severity score (items 2+3+5+6+7) is indicative of psychiatric symptoms in the clinical range for anxiety disorder, and a score of 10 or 11 is indicative of psychiatric symptoms in the subclinical range for anxiety disorder.

Outcome measures

Outcome measures
Measure
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
Placebo
n=33 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
Treatment Effect of NB-001 on the Pediatric Anxiety Rating Scale (PARS)
7.18 score on a scale
Standard Error 0.728
8.14 score on a scale
Standard Error 0.729

SECONDARY outcome

Timeframe: 6 weeks (Day 42/ET)

Population: Full Analysis Set: Includes all subjects in the Enrolled Analysis Set (those who meet all eligibility criteria and consent to participate in study) who have at least one valid post-baseline efficacy evaluation within each treatment period. Subjects are analyzed based on the treatment to which they were randomized in each treatment period.

The ADHD-RS-5 is a parent/guardian reported scale to measure behaviors of children and adolescents with ADHD. It consists of 18 items grouped into two subscales: inattention (items 1-9) and hyperactivity (items 10-18). Each item is scored on a scale ranging from 0 (reflecting no symptoms) to 3 (reflecting severe symptoms). The total inattention score (reported here) can range from a minimum value of 0 to a maximum value of 27. Higher total inattention scores reflect more severe symptoms.

Outcome measures

Outcome measures
Measure
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
Placebo
n=33 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
Treatment Effect of NB-001 on the Attention Deficit Hyperactivity Disorder-Rating Scale (ADHD-RS-5) - Inattention Score
13.47 score on a scale
Standard Error 0.947
13.80 score on a scale
Standard Error 0.941

SECONDARY outcome

Timeframe: 6 weeks (Day 42/ET)

Population: Full Analysis Set: Includes all subjects in the Enrolled Analysis Set (those who meet all eligibility criteria and consent to participate in study) who have at least one valid post-baseline efficacy evaluation within each treatment period. Subjects are analyzed based on the treatment to which they were randomized in each treatment period.

The ADHD-RS-5 is a parent/guardian reported scale to measure behaviors of children and adolescents with ADHD. It consists of 18 items grouped into two subscales: inattention (items 1-9) and hyperactivity (items 10-18). Each item is scored on a scale ranging from 0 (reflecting no symptoms) to 3 (reflecting severe symptoms). The total hyperactivity score (reported here) can range from a minimum value of 0 to a maximum value of 27. Higher total hyperactivity scores reflect more severe symptoms.

Outcome measures

Outcome measures
Measure
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
Placebo
n=33 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
Treatment Effect of NB-001 on the Attention Deficit Hyperactivity Disorder-Rating Scale (ADHD-RS-5) - Hyperactivity Score
7.82 score on a scale
Standard Error 0.629
8.02 score on a scale
Standard Error 0.623

SECONDARY outcome

Timeframe: 6 weeks (Day 42/ET)

Population: Includes all subjects in the Enrolled Analysis Set (those who meet all eligibility criteria and consent to participate in study) who have at least one valid post-baseline efficacy evaluation within each treatment period. Subjects are analyzed based on the treatment to which they were randomized in each treatment period.

The SRS-2 identifies the presence and severity of social impairment within the autism spectrum. It is a 65-item, parent-completed questionnaire which incorporates 5 content areas of social deficits. The sum of all items is calculated to provide a maximum total score of 195. However, a total derived T-score is calculated centrally and reported for this trial. A higher T-score indicates more severe impairment. The population mean T-score is 50, with a standard deviation of 10. Thus, a T-score considered within the normal range is 59 or below (i.e., minimum T-score value), and a T-score indicating a severe range is 76 or above (i.e., maximum T-score value). Scores between 60-75 fall into the mild to moderate range.

Outcome measures

Outcome measures
Measure
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
Placebo
n=33 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
Treatment Effect of NB-001 on the Social Responsiveness Scale, Second Edition (SRS-2)
62.42 T-score
Standard Error 1.005
63.27 T-score
Standard Error 1.019

OTHER_PRE_SPECIFIED outcome

Timeframe: End of Treatment; approximately 13 weeks of trial participation

Optional qualitative exit interviews were conducted with clinicians and parent/guardian(s) of subjects who completed the protocol.

Outcome measures

Outcome data not reported

Adverse Events

NB-001

Serious events: 0 serious events
Other events: 18 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 24 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
NB-001
n=33 participants at risk
Active drug product, NB-001: Two (2) 100 mg capsules administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg. NB-001: NB-001 is a non-stimulant modulator of multiple metabotropic glutamate receptors (mGluRs).
Placebo
n=34 participants at risk
Placebo: Two (2) capsules (matching NB-001) administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce. Placebo: Matching, inactive placebo
Infections and infestations
Nasopharyngitis
9.1%
3/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
11.8%
4/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
Infections and infestations
Upper respiratory tract infection
3.0%
1/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
8.8%
3/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
Psychiatric disorders
Insomnia
3.0%
1/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
17.6%
6/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
Psychiatric disorders
Irritability
3.0%
1/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
8.8%
3/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
Psychiatric disorders
Anxiety
3.0%
1/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
5.9%
2/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
Psychiatric disorders
Panic attack
0.00%
0/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
5.9%
2/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
Gastrointestinal disorders
Abdominal pain upper
3.0%
1/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
8.8%
3/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
Gastrointestinal disorders
Vomiting
6.1%
2/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
5.9%
2/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
Respiratory, thoracic and mediastinal disorders
Epistaxis
6.1%
2/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
5.9%
2/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
Respiratory, thoracic and mediastinal disorders
Cough
9.1%
3/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
0.00%
0/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
Respiratory, thoracic and mediastinal disorders
Nasal congestion
6.1%
2/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
2.9%
1/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
General disorders
Fatigue
9.1%
3/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
2.9%
1/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
General disorders
Pyrexia
6.1%
2/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
5.9%
2/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
Nervous system disorders
Headache
3.0%
1/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
5.9%
2/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.

Additional Information

Patrick Dougherty

Nobias Therapeutics, Inc.

Phone: (215) 821-4698

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place